Life Saving Drugs Program – Infantile-onset lysosomal acid-lipase deficiency disease (LAL-D) – Guidelines
We aim to provide documents in an accessible format. If you're having problems using a document with your accessibility tools, please contact us for help.
These guidelines include:
- General information about the Life Saving Drugs Program (LSDP)
- Treatment of infantile-onset LAL-D through the LSDP
- Drugs currently available for the treatment of infantile-onset LAL-D through the LSDP
- General, initial and ongoing eligibility requirements
- LSDP funding conditions
- Exclusion criteria.
Part of a collection: